Deepak Sambhara, MD

Dr. Sambara emphasizes the importance of collaboration and continuous learning for new retina specialists to thrive in their practice.

Experts discuss the future of retinal disease treatments, highlighting the promise of new therapies and the need for personalized patient care.

Experts discuss evolving strategies in treat-and-extend protocols for retinal diseases, emphasizing OCT's role in optimizing patient care and outcomes.

Experts discuss the safety of retinal treatments, addressing concerns about rare side effects and emphasizing the overall efficacy of these medications.

Experts discuss switching from 2 mg to 8 mg treatments for AMD and DME, emphasizing loading strategies and reduced steroid use in practice.

Healthcare professionals discuss the integration of second-generation medications into practice, emphasizing patient-specific responses and treatment challenges.

Experts discuss promising results from the Quasar trial for Eylea 8 mg, highlighting its potential impact on retinal vein occlusion treatment strategies.

Explore the latest findings from the Pulsar and Photon trials, highlighting innovative treatment extensions for AMD and DME patients.

Physicians discuss the promising durability and safety of Flibrice 8 mg, highlighting its potential to improve patient care in challenging cases.

Experts discuss advancements in retinal vascular disease treatment, focusing on the impact of next-generation anti-VEGF therapies and their safety.

Discover insights on evolving retinal care standards with next-generation anti-VEGF therapies from leading experts in the field.

Avacincaptad pegol, pegcetacoplan, and aflibercept 8mg do not increase risk of ocular hypertension and glaucoma, despite having higher volumes.